Treatment of Huntington's Disease in Patients with Depression

Depression is one of the most common psychiatric symptoms encountered in Huntington's disease and carries a significant negative impact on quality of life. Addressing it requires a specific clinical approach distinct from general HD management.

Clinical scenario: A patient with Huntington's disease who is also experiencing depression. This comorbidity is frequent in HD and warrants targeted pharmacological consideration alongside the primary neurological condition.

Treatment approach (partial overview)

Antidepressant therapy forms the basis of management in this setting, with the specific agent selected according to the patient's symptom profile — including whether sleep disruption is a factor. For recurrent presentations, the approach extends further.

Full regimen, drug selection criteria, and sequencing available in the complete protocol →

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.3389/fneur.2019.00710

Depression is one of the most common psychiatric symptoms seen in HD with a significant negative impact on quality of life.

An antidepressant may be suggested if depression occurs in HD (Grade B).

It is recommended to use a selective SSRI or a serotonin noradrenaline reuptake inhibitor (SNRI), or alternatively Mianserin or Mirtazapine, in case of sleep disruption.

In case of recurrent depression, long-term mood-stabilizer treatment may be introduced in complement to the treatment of the current episode to prevent relapses.

View source ↗